346 related articles for article (PubMed ID: 31243041)
1. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
[TBL] [Abstract][Full Text] [Related]
3. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
4. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
[TBL] [Abstract][Full Text] [Related]
6. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Marconi G; Giannini MB; Bagnato G; Simonetti G; Cerchione C; Mosquera Orgueira A; Musuraca G; Martinelli G
Expert Opin Drug Saf; 2021 Jul; 20(7):791-799. PubMed ID: 33853481
[TBL] [Abstract][Full Text] [Related]
7. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
[TBL] [Abstract][Full Text] [Related]
9. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
10. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
13. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
14. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
[TBL] [Abstract][Full Text] [Related]
18. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
20. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
Levis M
Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
